|View printer-friendly version|
Brings Wealth of Value Creation Experience to
In his new role, Mr. Knight will oversee business development, portfolio strategy and strategic marketing. He brings more than 20 years of experience in creating portfolio value at publicly-traded companies including,
“Jim is a highly-accomplished professional with an extensive skill set and knowledge that is applicable immediately, as we have started reporting encouraging early clinical data on our key programs,” said Mr. Mohanty. “I’m confident that his track record of value creation, particularly during his time at Questcor, where he helped drive portfolio expansion that grew revenue from
Most recently, Mr. Knight was the Vice President of Portfolio Strategy at Questcor from 2010 through 2014. Questcor was acquired by
“I am excited to join the
In addition to the development of therapeutics, BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.
To receive ongoing